Windmill

Windmill Therapeutics is a clinical-stage biotechnology company focused on developing novel adoptive T-cell therapies for the treatment of cancer. The company's proprietary platform leverages the 2B4 signaling pathway to enhance the persistence, potency, and polyfunctionality of T cells, addressing key limitations of current cell therapies in solid tumors. By utilizing marrow-infiltrating lymphocytes (MILs) and engineered T cells, Windmill aims to provide more durable clinical responses for patients with hard-to-treat malignancies. Their lead programs are currently being evaluated in clinical trials for both liquid and solid tumor indications.